Kalvista Common Stock Shares Outstanding vs Net Debt Analysis

KALV Stock

USD 12.11 0.44 3.77%

Kalvista Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kalvista Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kalvista Pharmaceuticals is a good investment. Please check the relationship between Kalvista Pharmaceuticals Common Stock Shares Outstanding and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Common Stock Shares Outstanding vs Net Debt

Common Stock Shares Outstanding vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kalvista Pharmaceuticals Common Stock Shares Outstanding account and Net Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between Kalvista Pharmaceuticals' Common Stock Shares Outstanding and Net Debt is -0.73. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Net Debt in the same time period over historical financial statements of Kalvista Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kalvista Pharmaceuticals' Common Stock Shares Outstanding and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Kalvista Pharmaceuticals are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Common Stock Shares Outstanding i.e., Kalvista Pharmaceuticals' Common Stock Shares Outstanding and Net Debt go up and down completely randomly.

Correlation Coefficient

-0.73

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from Kalvista Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.Issuance Of Capital Stock is likely to climb to about 58.6 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.

	2023	2024 (projected)
Net Interest Income	2.6M	2.7M
Non Recurring	1.3M	1.2M

Net Interest Income Non Recurring

Kalvista Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Long Term Debt
Total Assets		0.5	0.85	0.47	0.99	0.63	0.4	-0.6	-0.81	0.77	0.58	0.62	-0.22	1.0	0.74	0.64	-0.6	0.83	0.91	-0.3	0.89	1.0	-0.55	0.74	-0.09	0.33
Short Long Term Debt Total	0.5		0.38	-0.06	0.5	0.57	-0.23	-0.06	-0.65	0.51	0.22	0.6	0.36	0.49	0.48	0.4	0.04	0.53	0.49	-0.21	0.63	0.48	0.29	0.47	0.53	0.46
Other Current Liab	0.85	0.38		0.64	0.85	0.36	0.36	-0.44	-0.89	0.85	0.46	0.36	-0.32	0.81	0.65	0.43	-0.56	0.87	0.95	-0.2	0.91	0.85	-0.52	0.67	-0.05	0.32
Total Current Liabilities	0.47	-0.06	0.64		0.43	0.16	0.52	-0.56	-0.47	0.59	0.46	0.16	-0.23	0.44	0.33	0.28	-0.37	0.48	0.53	0.1	0.49	0.47	-0.52	0.34	-0.05	-0.14
Total Stockholder Equity	0.99	0.5	0.85	0.43		0.64	0.44	-0.61	-0.8	0.78	0.62	0.63	-0.14	0.99	0.78	0.65	-0.67	0.83	0.89	-0.43	0.87	0.99	-0.57	0.79	-0.02	0.31
Property Plant And Equipment Net	0.63	0.57	0.36	0.16	0.64		0.43	-0.66	-0.62	0.66	0.55	1.0	0.15	0.62	0.73	0.97	-0.47	0.54	0.49	-0.42	0.58	0.62	-0.36	0.71	0.27	0.18
Current Deferred Revenue	0.4	-0.23	0.36	0.52	0.44	0.43		-0.81	-0.32	0.45	0.58	0.41	-0.2	0.39	0.42	0.56	-0.71	0.32	0.37	-0.43	0.29	0.4	-0.82	0.42	-0.15	-0.59
Net Debt	-0.6	-0.06	-0.44	-0.56	-0.61	-0.66	-0.81		0.5	-0.6	-0.87	-0.64	0.13	-0.61	-0.69	-0.73	0.72	-0.34	-0.48	0.33	-0.45	-0.61	0.76	-0.68	-0.01	0.28
Retained Earnings	-0.81	-0.65	-0.89	-0.47	-0.8	-0.62	-0.32	0.5		-0.92	-0.52	-0.62	0.22	-0.77	-0.76	-0.61	0.48	-0.87	-0.93	0.21	-0.97	-0.8	0.4	-0.76	-0.13	-0.33
Accounts Payable	0.77	0.51	0.85	0.59	0.78	0.66	0.45	-0.6	-0.92		0.6	0.66	-0.08	0.73	0.81	0.7	-0.61	0.82	0.83	-0.35	0.86	0.76	-0.53	0.81	0.24	0.23
Cash	0.58	0.22	0.46	0.46	0.62	0.55	0.58	-0.87	-0.52	0.6		0.53	0.02	0.6	0.85	0.58	-0.77	0.33	0.44	-0.42	0.46	0.59	-0.66	0.85	0.17	-0.06
Non Current Assets Total	0.62	0.6	0.36	0.16	0.63	1.0	0.41	-0.64	-0.62	0.66	0.53		0.22	0.61	0.71	0.96	-0.43	0.54	0.48	-0.44	0.57	0.61	-0.31	0.69	0.33	0.18
Non Currrent Assets Other	-0.22	0.36	-0.32	-0.23	-0.14	0.15	-0.2	0.13	0.22	-0.08	0.02	0.22		-0.21	0.04	0.08	0.15	-0.27	-0.39	-0.52	-0.3	-0.23	0.43	0.02	0.89	-0.03
Cash And Short Term Investments	1.0	0.49	0.81	0.44	0.99	0.62	0.39	-0.61	-0.77	0.73	0.6	0.61	-0.21		0.73	0.62	-0.6	0.79	0.88	-0.3	0.86	1.0	-0.54	0.73	-0.1	0.32
Common Stock Total Equity	0.74	0.48	0.65	0.33	0.78	0.73	0.42	-0.69	-0.76	0.81	0.85	0.71	0.04	0.73		0.75	-0.81	0.63	0.64	-0.56	0.7	0.74	-0.62	1.0	0.24	0.31
Common Stock Shares Outstanding	0.64	0.4	0.43	0.28	0.65	0.97	0.56	-0.73	-0.61	0.7	0.58	0.96	0.08	0.62	0.75		-0.59	0.56	0.51	-0.46	0.56	0.63	-0.52	0.73	0.2	0.13
Non Current Liabilities Total	-0.6	0.04	-0.56	-0.37	-0.67	-0.47	-0.71	0.72	0.48	-0.61	-0.77	-0.43	0.15	-0.6	-0.81	-0.59		-0.49	-0.49	0.65	-0.45	-0.61	0.92	-0.81	0.08	0.04
Other Current Assets	0.83	0.53	0.87	0.48	0.83	0.54	0.32	-0.34	-0.87	0.82	0.33	0.54	-0.27	0.79	0.63	0.56	-0.49		0.91	-0.2	0.93	0.83	-0.44	0.64	-0.08	0.36
Other Stockholder Equity	0.91	0.49	0.95	0.53	0.89	0.49	0.37	-0.48	-0.93	0.83	0.44	0.48	-0.39	0.88	0.64	0.51	-0.49	0.91		-0.15	0.97	0.9	-0.48	0.66	-0.13	0.31
Total Liab	-0.3	-0.21	-0.2	0.1	-0.43	-0.42	-0.43	0.33	0.21	-0.35	-0.42	-0.44	-0.52	-0.3	-0.56	-0.46	0.65	-0.2	-0.15		-0.13	-0.3	0.38	-0.55	-0.49	0.09
Property Plant And Equipment Gross	0.89	0.63	0.91	0.49	0.87	0.58	0.29	-0.45	-0.97	0.86	0.46	0.57	-0.3	0.86	0.7	0.56	-0.45	0.93	0.97	-0.13		0.88	-0.4	0.7	-0.02	0.38
Total Current Assets	1.0	0.48	0.85	0.47	0.99	0.62	0.4	-0.61	-0.8	0.76	0.59	0.61	-0.23	1.0	0.74	0.63	-0.61	0.83	0.9	-0.3	0.88		-0.56	0.74	-0.1	0.33
Short Term Debt	-0.55	0.29	-0.52	-0.52	-0.57	-0.36	-0.82	0.76	0.4	-0.53	-0.66	-0.31	0.43	-0.54	-0.62	-0.52	0.92	-0.44	-0.48	0.38	-0.4	-0.56		-0.61	0.36	0.22
Common Stock	0.74	0.47	0.67	0.34	0.79	0.71	0.42	-0.68	-0.76	0.81	0.85	0.69	0.02	0.73	1.0	0.73	-0.81	0.64	0.66	-0.55	0.7	0.74	-0.61		0.23	0.33
Other Assets	-0.09	0.53	-0.05	-0.05	-0.02	0.27	-0.15	-0.01	-0.13	0.24	0.17	0.33	0.89	-0.1	0.24	0.2	0.08	-0.08	-0.13	-0.49	-0.02	-0.1	0.36	0.23		0.04
Long Term Debt	0.33	0.46	0.32	-0.14	0.31	0.18	-0.59	0.28	-0.33	0.23	-0.06	0.18	-0.03	0.32	0.31	0.13	0.04	0.36	0.31	0.09	0.38	0.33	0.22	0.33	0.04

Click cells to compare fundamentals

Kalvista Pharmaceuticals Account Relationship Matchups

Kalvista Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.1M	92.5M	272.0M	203.9M	183.2M	88.7M
Short Long Term Debt Total	54K	1.6M	5.9M	8.2M	8.2M	4.6M
Other Current Liab	5.5M	6.9M	7.0M	9.1M	29K	27.6K
Total Current Liabilities	18.1M	7.7M	9.8M	11.6M	15.0M	4.1M
Total Stockholder Equity	96.7M	83.8M	257.2M	185.1M	161.0M	66.4M
Property Plant And Equipment Net	3.7M	7.5M	10.0M	10.8M	12.4M	13.0M
Net Debt	(14.1M)	(44.7M)	(22.5M)	(48.0M)	(43.2M)	(41.0M)
Retained Earnings	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)	(76.3M)
Accounts Payable	2.9M	1.7M	2.0M	3.6M	4.8M	2.0M
Cash	32.0M	15.8M	50.6M	30.7M	56.2M	32.8M
Non Current Assets Total	3.8M	7.7M	10.2M	10.9M	12.5M	13.1M
Cash And Short Term Investments	100.8M	67.7M	248.9M	166.2M	149.4M	77.5M
Common Stock Total Equity	17K	18K	24K	25K	34K	18.2K
Common Stock Shares Outstanding	17.7M	19.1M	24.5M	27.9M	32.1M	33.7M
Liabilities And Stockholders Equity	92.5M	272.0M	203.9M	183.2M	210.7M	221.2M
Non Current Liabilities Total	1.1M	5.0M	7.2M	7.1M	6.4M	11.2M
Other Current Assets	4.5M	4.9M	10.6M	6.4M	1.0M	959.5K
Other Stockholder Equity	207.2M	426.4M	439.1M	507.1M	(75K)	(71.3K)
Total Liab	21.4M	8.8M	14.8M	18.8M	22.2M	7.1M
Property Plant And Equipment Gross	2.4M	3.7M	7.5M	10.0M	10.8M	764.8K
Total Current Assets	115.5M	88.7M	264.3M	193.6M	172.3M	85.2M
Accumulated Other Comprehensive Income	(1.9M)	(1.9M)	(1.4M)	(3.9M)	(3.1M)	(659.4K)
Short Term Debt	54K	588K	863K	977K	1.1M	1.2M
Common Stock	17K	18K	24K	25K	34K	15.9K
Capital Surpluse	191.1M	207.2M	426.4M	439.1M	507.1M	115.8M
Property Plant Equipment	2.4M	2.0M	1.8M	2.2M	2.9M	1.3M
Net Tangible Assets	83.8M	257.2M	185.1M	161.0M	43.1M	40.9M
Net Receivables	11.3M	16.5M	10.4M	14.1M	16.6M	2.1M
Retained Earnings Total Equity	(71.7M)	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)
Net Invested Capital	83.8M	257.2M	185.1M	161.0M	185.2M	132.4M
Net Working Capital	81.0M	254.5M	182.1M	157.3M	180.9M	132.0M
Capital Lease Obligations	1.6M	5.9M	8.2M	8.2M	9.5M	9.9M
Capital Stock	18K	24K	25K	34K	39.1K	26.0K

Pair Trading with Kalvista Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kalvista Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kalvista Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kalvista Stock

0.78

ETON

Eton Pharmaceuticals

Pair Corr

Moving against Kalvista Stock

0.5

DSGN

Design Therapeutics

Pair Corr

The ability to find closely correlated positions to Kalvista Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kalvista Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kalvista Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kalvista Pharmaceuticals to buy it.

The correlation of Kalvista Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kalvista Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kalvista Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kalvista Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC